Huan Peng1, Daniele Rossetto2,3, Sheref S Mansy2,3, Maria C Jordan4, Kenneth P Roos4, Irene A Chen1. 1. Department of Chemical and Biomolecular Engineering, University of California, Los Angeles, California 90095, United States. 2. Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2, Canada. 3. CIBIO, University of Trento, 38123 Povo, Trento, Italy. 4. Department of Physiology, David Geffen School of Medicine at the University of California, Los Angeles, California 90095, United States.
Abstract
Infections caused by drug-resistant bacteria, particularly Gram-negative organisms, are increasingly difficult to treat using antibiotics. A potential alternative is "phage therapy", in which phages infect and lyse the bacterial host. However, phage therapy poses serious drawbacks and safety concerns, such as the risk of genetic transduction of antibiotic resistance genes, inconsistent pharmacokinetics, and unknown evolutionary potential. In contrast, metallic nanoparticles possess precise, tunable properties, including efficient conversion of electronic excitation into heat. In this work, we demonstrate that engineered phage-nanomaterial conjugates that target the Gram-negative pathogen Pseudomonas aeruginosa are highly effective as a treatment of infected wounds in mice. Photothermal heating, performed as a single treatment (15 min) or as two treatments on consecutive days, rapidly reduced the bacterial load and released Zn2+ to promote wound healing. The phage-nanomaterial treatment was significantly more effective than systemic standard-of-care antibiotics, with a >10× greater reduction in bacterial load and ∼3× faster healing as measured by wound size reduction when compared to fluoroquinolone treatment. Notably, the phage-nanomaterial was also effective against a P. aeruginosa strain resistant to polymyxins, a last-line antibiotic therapy. Unlike these antibiotics, the phage-nanomaterial showed no detectable toxicity or systemic effects in mice, consistent with the short duration and localized nature of phage-nanomaterial treatment. Our results demonstrate that phage therapy controlled by inorganic nanomaterials can be a safe and effective antimicrobial strategy in vivo.
Infections caused by drug-resistant bacteria, particularly Gram-negative organisms, are increasingly difficult to treat using antibiotics. A potential alternative is "phage therapy", in which phages infect and lyse the bacterial host. However, phage therapy poses serious drawbacks and safety concerns, such as the risk of genetic transduction of antibiotic resistance genes, inconsistent pharmacokinetics, and unknown evolutionary potential. In contrast, metallic nanoparticles possess precise, tunable properties, including efficient conversion of electronic excitation into heat. In this work, we demonstrate that engineered phage-nanomaterial conjugates that target the Gram-negative pathogen Pseudomonas aeruginosa are highly effective as a treatment of infected wounds in mice. Photothermal heating, performed as a single treatment (15 min) or as two treatments on consecutive days, rapidly reduced the bacterial load and released Zn2+ to promote wound healing. The phage-nanomaterial treatment was significantly more effective than systemic standard-of-care antibiotics, with a >10× greater reduction in bacterial load and ∼3× faster healing as measured by wound size reduction when compared to fluoroquinolone treatment. Notably, the phage-nanomaterial was also effective against a P. aeruginosa strain resistant to polymyxins, a last-line antibiotic therapy. Unlike these antibiotics, the phage-nanomaterial showed no detectable toxicity or systemic effects in mice, consistent with the short duration and localized nature of phage-nanomaterial treatment. Our results demonstrate that phage therapy controlled by inorganic nanomaterials can be a safe and effective antimicrobial strategy in vivo.
Infections
caused by multidrug-resistant
bacteria pose an increasing threat to modern medicine.[1−3] Multidrug-resistant organisms presently cause >700,000 deaths
annually,
and this number is projected to reach 10 million, exceeding the number
of deaths from cancer, by 2050.[4] The economic
burden associated with drug-resistant pathogens is also high, estimated
at $133 billion annually in the United States alone.[5] In addition to improved antibiotic stewardship, the development
of alternative antimicrobial classes, particularly for multidrug-resistant
Gram-negative organisms, is a crucial element of the response to this
problem.[4] One potential alternative antimicrobial
agent is phages,[6] but phage therapy, as
traditionally envisioned, also poses serious disadvantages. Naturally
occurring phages can carry toxin genes (e.g., cholera toxin),[7] transfer antibiotic resistance among pathogens
(e.g., among Staphylococcus aureus),[8] and physically support a pathological biofilm,[9,10] causing biosafety concerns. Furthermore, phage self-replication
causes unusual or unpredictable pharmacokinetics and pharmacodynamics,
and rapid cell lysis can result in unwanted release of bacterial endotoxins.[11,12]At the same time, engineered phages are increasingly exploited
for a variety of applications.[13] For therapeutic
aims, one possible approach to mitigate the problems of phage therapy
is to use a nonlytic phage for bacterial attachment, while relying
on a conjugated nanomaterial, specifically gold nanorods (AuNRs),
to destroy the bacteria as well as the phage in a controlled manner.
AuNRs are excited by light, leading to coherent electronic oscillation
(surface plasmon resonance), whose energy is released as heat. This
photothermal property has been used therapeutically to kill malignant
cells,[14,15] particularly when the nanomaterial is tuned
to absorb in near-infrared (NIR) wavelengths, which can penetrate
a few centimeters into the skin.[16−18] M13 is a well-studied,
nonlytic, filamentous Escherichia coli phage that
is widely used as a platform for phage display.[19,20] The coat of M13 is primarily composed of ∼2700 copies of
the g8p protein, in addition to several copies of the receptor-binding
protein (g3p). Each g8p possesses multiple solvent-accessible carboxylates
in addition to an exposed N-terminus, allowing chemical conjugation.[21] M13 can be rationally designed to attach to
different Gram-negative pathogens by swapping the receptor-binding
domain of g3p.[22,23] Phage-AuNR bioconjugates (“phanorods”)
have been shown to be effective against bacterial cells in vitro,
through the photothermal effect.[24] However,
whether the in vitro properties translate to in vivo efficacy as an
antimicrobial treatment is unknown. Potential issues with phanorod
treatment in vivo include: inactivation or clearance of phanorods
by the immune system, inhibition of the antimicrobial effect by a
biofilm, inhibition of receptor binding by the physiological medium,
possible toxicity of phanorods to the animal, or insufficient selectivity
causing thermal damage to animal tissue.Wounds represent an
important medical burden, estimated at 2–4%
of total health care costs.[25] Multidrug-resistant Pseudomonas aeruginosa, a Gram-negative microorganism, is
a particular concern in chronic and acute wound infections, including
burns, especially in nosocomial settings.[26−29] Indeed, P. aeruginosa has been designated as a critical priority 1 bacterial pathogen
by the World Health Organization as well as a “serious threat”
microbe by the Centers for Disease Control and Prevention.[5,30] Multiple murine models of P. aeruginosa wound infections
have been described, including for open wounds.[31] Although bioavailability can be a concern for phages, wounds
are anatomically accessible for direct topical application of phage-based
reagents,[32] and wounds can also be readily
exposed to light for photothermal activation of AuNRs. A chimeric
phage, M13-g3p(Pf1), was previously engineered to bind to the type
IV pili of P. aeruginosa, a virulence factor involved
in both twitching motility and attachment sensing, which has been
recently suggested as a therapeutic target.[33−36]In this work, we prepared
a material, phanorod-Zn, based on phanorods
that were synthesized by conjugating M13-g3p(Pf1) to AuNRs absorbing
in the NIR wavelengths. The design of phanorod-Zn comprises three
modular modifications to the phage. First, tight binding to the targeted
host cell (P. aeruginosa) is accomplished through
modification of the receptor-binding domain, namely the N-terminal
domain of the minor coat protein g3p, of the phage. For the phanorod-Zn
described in this work, the receptor-binding domain of M13, which
attaches to the F pilus of E. coli, has been swapped
for the receptor-binding domain of phage Pf1, which attaches to the
type IV pili of P. aeruginosa. This modification
directs the chimeric phage to bind the receptor pili of P.
aeruginosa.[22,37] Second, although the chimeric
phages are not expected to replicate on the new host, cell-killing
activity is conferred through conjugation of a photothermal agent,
AuNRs, to the chimeric phage. Since the phages are approximately 1
μm in length, each virion is able to carry multiple AuNRs, which
are approximately 50 nm in length.[37] We
have previously shown that such phanorod (phage-AuNR) conjugates have
excellent cell-killing properties in vitro,[37] although the efficacy in vivo was not previously studied. Third,
for the in vivo application studied here, we further loaded the chimeric
phages with a zinc-binding peptide (Pol-K, described below), in order
to deliver Zn2+ to the bacterial infection. The motivation
behind this third modification is two-fold. Zinc (Zn2+)
has been observed to both promote wound healing[38,39] and to inhibit bacterial growth, likely through multiple molecular
mechanisms. Therefore, Zn2+ release would be a desirable
feature for a material treating wound infections. We decorated the
phanorods with a zinc-binding peptide (Pol-K) designed to release
Zn2+ upon photothermal heating (phanorod-Zn). The dodecapeptide
Pol-K represents a minimal Zn2+-binding motif, based on
a bioinformatic analysis of Zn2+-binding protein sequences.
While the cytotoxicity of metal nanoparticles depends on multiple
factors, including size, shape, charge, cell line, and the specific
application, potential cytotoxicity of colloidal gold can be mitigated
by surface coating with polyethylene glycol (PEG).[40] Zn2+ is used as a dietary supplement and medical
treatment, including for wound healing,[41] with zinc oxide nanomaterials being known for low toxicity,[42] although high amounts of Zn2+ can
lead to toxicity in specific applications.[43] Thus, the phanorod and phanorod-Zn were coated with PEG, and cytotoxicity
was also assessed, in this study.In this design, Pol-K acts
as a carrier for Zn2+, and
the phage acts as a targeting agent to bring both the AuNRs as well
as bound Zn2+ to the bacterial cells. Phages have been
shown to possess advantages over antibodies as targeting agents, having
both greater stability against environmental factors as well as greater
cell-killing efficiency.[37] Photothermal
activation of the AuNRs should then cause localized heating that kills
the bacterial cells, and photothermal release of Zn2+ should
potentiate the antibacterial activity and promote wound healing. Using
a mouse model of P. aeruginosa-infected wounds, we
assessed the efficacy and toxicity of phanorod and phanorod-Zn treatment
(Scheme ). Our experimental
results show that phanorod and phanorod-Zn treatments were highly
effective, yielding faster wound healing compared to standard antibiotic
treatments (e.g., ciprofloxacin) or antibody-conjugated AuNRs. Phanorod-Zn
treatment was also effective when administered late into infection
and prevented death in cases of otherwise terminal wounds. Wounds
infected by a strain of P. aeruginosa that was resistant
to last-line antibiotic therapy (polymyxins) were also effectively
treated by phanorod-Zn. Serum biomarkers and histological analysis
did not show systemic toxicity of phanorods or phanorod-Zn to the
mice, in contrast to the fluoroquinolone and polymyxin antibiotics.
The results indicate that phage-based nanomaterials, such as phanorods
and phanorod-Zn, may be a promising alternative antimicrobial strategy
for treatment of multidrug-resistant bacterial infections of wounds.
Scheme 1
Treatment of a P. aeruginosa-Infected Wound by Phage-Conjugated
AuNRs Decorated with Zn2+
Treatment is initiated
0–2
days after wound inoculation. The phage-based reagent is applied to
the wound and allowed to bind for 30 min. The wound is irradiated
with near-infrared light for 15 min to trigger photothermal ablation
of P. aeruginosa and release of Zn2+;
irradiation may be repeated the next day. Wound healing is observed
over the next ∼10 days.
Treatment of a P. aeruginosa-Infected Wound by Phage-Conjugated
AuNRs Decorated with Zn2+
Treatment is initiated
0–2
days after wound inoculation. The phage-based reagent is applied to
the wound and allowed to bind for 30 min. The wound is irradiated
with near-infrared light for 15 min to trigger photothermal ablation
of P. aeruginosa and release of Zn2+;
irradiation may be repeated the next day. Wound healing is observed
over the next ∼10 days.
Results and Discussion
Synthesis
of Phanorod-Zn and Loading of Zn2+
Phage-AuNRs
(“phanorods”) were synthesized as reported
previously.[24] The phage used in this work,
M13-g3p(Pf1), was engineered as a chimera of M13 and the P.
aeruginosa phage Pf1. In M13-g3p(Pf1), the receptor-binding
domain of M13 (N-terminal domain of g3p) was replaced by the corresponding
domain from Pf1, thereby enabling the chimera M13-g3p(Pf1) to attach
to P. aeruginosa via type IV pili. The AuNRs (average
length, 53.2 nm; average width, 13.7 nm) were thiolated, conjugated
to phages, and passivated by HOOC-PEG-SH.Phanorod-Zn was prepared
by conjugation of the synthetic Zn2+-binding peptide Pol-K
(amino acid sequence: GCFCEDACDKCG; Kd,Zn for Zn2+ = 41 μM; Figure S1a–d) with phanorods through 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
(EDC) chemistry. Available carboxylic acid groups for conjugation
include three solvent-accessible residues (Glu2, Asp4, and Asp5) per
copy of the major coat protein, g8p (of which there are ∼2700
copies per particle),[44] as well as –
COOH groups on the surface of AuNRs. The Fourier transform infrared
(FTIR) spectra of phanorods, Pol-K, and phanorod-Zn showed that phanorod-Zn
exhibited increased signals at 1510 and 3036 cm–1 (matching the C–C and C–H stretching, respectively,
of the phenyl group of Pol-K) and at 2550 cm–1 (from
the S–H stretching of the thiol groups), indicating successful
peptide conjugation (Figure S1e). Conjugated
Pol-K on phanorod-Zn was quantified with Ellman’s assay (measuring
added thiol groups compared to phanorods), and the phage particles
were quantified by real-time PCR, allowing estimation that each phanorod-Zn
carries 1769 ± 357 Pol-K peptides (mean ± standard deviation,
n = 3 samples). Finally, Zn2+ was loaded by overnight incubation
with ZnCl2 followed by washing.The loading capacity
of phanorod-Zn for Zn2+ was measured
by quantifying Zn2+ by inductively coupled plasma mass
spectrometry (ICP-MS). While phanorods (without Pol-K) did not bind
detectable Zn2+ (i.e., <0.002 ng/mL), phanorod-Zn was
found to be loaded by 1410 ± 672 Zn2+ ions per phanorod-Zn
particle, close to the expectation based on a 1:1 stoichiometry with
the amount of Pol-K as measured by Ellman’s assay. Thus, this
bioconjugate contained approximately one Pol-K copy for every two
copies of g8p, and each Pol-K copy was bound to ∼0.8 Zn2+ ion on average.Additionally, the binding affinity
of phanorods and phanorod-Zn
to host cells was measured to assess the strength of attachment to
host cells. The phage-based reagents were mixed with host cells, centrifuged,
and washed, and the amount bound was determined by quantitative PCR
(Supporting Methods). The dissociation
constants (Kd) of M13-g3p(Pf1), phanorods,
and phanorod-Zn for the host cell P. aeruginosa (ATCC25102
(Schroeter) Migula) were found to be similar to each other (5–6
pM; Figure S2a), with affinities similar
to that seen for the interaction between M13 and E. coli (2 pM).[45] This result indicates that
bioconjugation and modification with Pol-K did not substantially perturb
the binding affinity to host cells.
Release of Zn2+ from Phanorod-Zn
The Pol-K
dodecapeptide was designed based on the compact Zn2+-binding
motif of RNA polymerase II and contains four cysteine ligands that
tetrahedrally coordinate Zn2+. We hypothesized that release
of Zn2+ would occur at high temperatures, due to an increase
in the off-rate of the bound Zn2+, structural perturbations
to Pol-K, or both.[46,47] Laser irradiation of AuNRs leads
to localized plasmonic heating and temperature increase (characterized
further below). We therefore irradiated phanorod-Zn in PBS and monitored
release of Zn2+ by ICP-MS. After irradiation for 15 min,
the bulk temperature reached 55 °C, and the cumulative Zn2+ ion release reached ∼1.06 ppm (17 μM) after
1 day (Figure a).
Additional laser irradiation on day 2 (15 min per day, again giving
a bulk temperature increase to 55 °C) resulted in additional
release of Zn2+, yielding a concentration of 1.69 ppm (26
μM). Laser irradiation was again applied on day 3, but no significant
additional release of Zn2+ was detected on day 3 (Figure b), indicating that
maximal release was achieved after 2 days. When no laser was applied,
<0.2 ppm (3.1 μM) of Zn2+ was released after 3
days of incubation in PBS (Figure ). Phanorods (in the absence of conjugation to Pol-K)
did not capture detectable Zn2+ ions as assessed by ICP-MS,
indicating that the capture and release of Zn2+ ions were
attributable to the conjugated Pol-K peptide.
Figure 1
Release of Zn2+ ions by phanorod-Zn, measured by ICP-MS.
Cumulative Zn2+ release curves of phanorod-Zn (1014 phage per mL) in PBS buffer after a single 15 min irradiation (a)
or with daily irradiation (15 min/day for 3 days) (b). The amount
of Zn2+ loaded in phanorod-Zn is 15.29 ± 0.73 ppm
(234 ± 11 μM) before irradiation. Error bars indicate mean
± standard deviation (n = 3 independent samples).
Release of Zn2+ ions by phanorod-Zn, measured by ICP-MS.
Cumulative Zn2+ release curves of phanorod-Zn (1014 phage per mL) in PBS buffer after a single 15 min irradiation (a)
or with daily irradiation (15 min/day for 3 days) (b). The amount
of Zn2+ loaded in phanorod-Zn is 15.29 ± 0.73 ppm
(234 ± 11 μM) before irradiation. Error bars indicate mean
± standard deviation (n = 3 independent samples).To determine whether Zn2+ release could
be due to higher
temperatures alone, we measured the effect of bulk temperature, without
laser irradiation, on the rate of ion release. Although Zn2+ is spectroscopically silent, Co2+ is a well-established
substitute of Zn2+ for spectroscopic study of Zn2+-binding proteins.[48] Using this system,
ligand release from Pol-K was observed to be negligible at room temperature,
but increased with increasing bulk temperature, in the absence of
irradiation (Figure S1d). Thus, heating
by itself accelerates the rate of metal ligand release. We further
tested the dependence of Zn2+ release on photothermal heating
at different levels in the context of phanorod-Zn. We exposed phanorod-Zn
to different intensities of laser irradiation, resulting in a range
of different bulk temperatures, and quantified Zn2+ release
by ICP-MS. As expected, while Zn2+ release was negligible
at lower intensity, greater release was seen at higher intensity (Figure S2c). Therefore, the increased rate of
ligand ion release at higher temperatures is a probable mechanism
for Zn2+ release from phanorod-Zn upon photothermal heating.It is also possible that laser irradiation might denature Pol-K
of the phanorod-Zn, reducing Zn2+-loading and consequently
causing release of Zn2+. We measured the loading capacity
of phanorod-Zn, with or without irradiation, by incubating with a
solution of ZnCl2, separating phanorod-Zn by centrifugation
and washing, and quantifying bound Zn2+ by ICP-MS. The
results showed that laser irradiation (15 min) does not measurably
affect loading capacity (Figure S2b). Since
the coordination strength could be affected without loss of loading
capacity, we also tested whether laser irradiation caused destruction
of the thiol groups required to coordinate Zn2+ (e.g.,
by denaturation through oxidation).[49] We
quantified the thiol groups by Ellman’s assay after irradiation
and found that irradiation caused a 6.1% decrease in thiols (from
1.23 ± 0.035 mM to 1.15 ± 0.026 mM thiols; p = 0.0034). Although this decrease in thiols did not appear to reduce
overall loading capacity, it may reduce the coordination strength
and thus increase the rate of Zn2+ release.
Photothermal
Stability and Efficiency of Phanorods and Phanorod-Zn
The
photothermal stability and efficiency of AuNR, phanorods and
phanorod-Zn solutions ([Au] = 3.3 μM) was measured under gradually
increased 808 nm near-infrared (NIR) laser irradiation (0.3 W cm–2), close to the absorbance peak of the AuNRs (Figure S1g,h). The solution temperatures of AuNRs,
phanorods, and phanorod-Zn reached 59.8 ± 0.78 °C, 56.6
± 0.62 °C, and 55.2 ± 0.17 °C after 5 min, respectively
(n = 5 in all cases). Under the same treatment, the
temperature of PBS buffer increased by <2 °C, confirming that
the AuNRs, phanorods, and phanorod-Zn efficiently convert the energy
of NIR light into heat. We also assessed photothermal reversibility
and stability over multiple irradiation cycles (Figure S3). No significant deterioration was observed over
five on/off cycles. To determine whether conjugation of phages affected
the photothermal conversion efficiency of the AuNRs, the conversion
efficiency (η) of light into heat was quantitatively estimated
by the time constant (τs) and the maximum steady-state
temperature. The photothermal conversion efficiency was slightly perturbed
by phage modification, with η = 42.6%, 40.6%, and 38.9% for
AuNRs, phanorods, and phanorod-Zn (Figure S3), respectively, which is consistent with an enhancement in scattered
light by the phage and peptide.[50,51] Nevertheless, photothermal
properties of the AuNRs were largely preserved in the bioconjugates.
Stability and Infectivity of Bioconjugates
We studied
the stability of phanorod-Zn after storing at 4 °C in a sealed
flask (under air) for 15 days. The photothermal heating curves, binding
curves for P. aeruginosa, and Zn2+-loading
capacity are similar when measured on day 1 and day 15 (Figure S2d–f), indicating that these properties
of the bioconjugates were stable during this storage.To determine
whether the biological activity of the bioconjugates was affected
by laser irradiation, we measured replication of phages after irradiation.
Since the chimeric phage M13-g3p(Pf1) is not expected to propagate
in P. aeruginosa or to attach to E. coli due to the mismatch of host species, we studied bioconjugates using
M13KE phage, that is, M13KE-AuNR and M13KE-AuNR-Pol-K. These bioconjugates
were prepared and irradiated with laser by the same method as described
above. Afterward, their ability to propagate on E. coli ER2738 was tested by incubation with the host bacteria. Putative
phage DNA was extracted and quantified with qPCR.[22] No DNA was detected from propagation of the treated sample
(Figure S4), indicating that the infectivity
of the phages was inactivated by the laser treatment, as expected
due to thermal denaturation of the phages. These results are consistent
with previous observations.[37]
Antibacterial
Activity of Phanorod-Zn with Planktonic P. aeruginosa In Vitro
Prior work[24] demonstrated
the bacteriocidal effect of phanorods in vitro.
Conjugation of Pol-K and Zn2+-loading of phanorods (i.e.,
phanorod-Zn) was expected to increase the antibacterial effect due
to the known antimicrobial effects of Zn2+.[52,53] We first tested the bacteriocidal activity of phanorod-Zn in a suspension
of P. aeruginosa cells. Irradiation of phanorods
and phanorod-Zn (1014 particles/mL) by 808 nm near-infrared
(NIR) light (0.3 W cm–2) for 15 min resulted in
an equilibrium bulk temperature of ∼55 °C (Figure S1). Without irradiation, P. aeruginosa suspensions incubated with phanorods or phanorod-Zn showed no antibacterial
activity (Figure a).
However, after 15 min of irradiation, approximately 88.5 ± 3.1%
and 97.5 ± 1.5% of P. aeruginosa colony-forming
units (cfu) were destroyed in the phanorod and phanorod-Zn groups,
respectively, showing significantly greater cell-killing by phanorod-Zn
than phanorods (p < 0.001; Figure b). Transmission electron microscopy (TEM)
of P. aeruginosa cells showed that phanorod-Zn carried
multiple AuNRs to the cells, and cell morphology was grossly altered
after photothermal treatment with phanorod-Zn (Figure S5a–c,f,g).
Figure 2
Antibacterial effect of phanorods and
phanorod-Zn in vitro, measured
by cfu. P. aeruginosa cells in suspension were exposed
to phanorods and phanorod-Zn without irradiation. The presence of
these reagents did not affect bacterial survival (a) (control = no
phanorods or phanorod-Zn added). With NIR laser irradiation, cell
survival was reduced in the presence of phanorods, and phanorod-Zn
showed a significantly greater reduction in cell survival (b). If
repeated washing was applied to remove released Zn2+ (c),
the colony counts (with NIR laser irradiation) were similar between
phanorods and phanorod-Zn exposure. Colony counts of a treated P. aeruginosa biofilm (d) show trends similar to P. aeruginosa in suspension (b). Error bars are standard
deviation (n = 5): **p < 0.01,
***p < 0.001, NS, not significant (p > 0.05, two-sided t test).
Antibacterial effect of phanorods and
phanorod-Zn in vitro, measured
by cfu. P. aeruginosa cells in suspension were exposed
to phanorods and phanorod-Zn without irradiation. The presence of
these reagents did not affect bacterial survival (a) (control = no
phanorods or phanorod-Zn added). With NIR laser irradiation, cell
survival was reduced in the presence of phanorods, and phanorod-Zn
showed a significantly greater reduction in cell survival (b). If
repeated washing was applied to remove released Zn2+ (c),
the colony counts (with NIR laser irradiation) were similar between
phanorods and phanorod-Zn exposure. Colony counts of a treated P. aeruginosa biofilm (d) show trends similar to P. aeruginosa in suspension (b). Error bars are standard
deviation (n = 5): **p < 0.01,
***p < 0.001, NS, not significant (p > 0.05, two-sided t test).Live/dead staining confirmed that phanorod-Zn resulted in significantly
greater bacterial cell-killing compared to phanorods (phanorods: 87.2
± 3.9% cell death; phanorod-Zn: 98.8 ± 1.1% cell death; P < 0.001) (Figures S6 and S7). Because the heating profiles of phanorods and phanorod-Zn are
similar (Figures S1g and S3), the higher
cell-killing efficiency of phanorod-Zn was suspected to be due the
released Zn2+ ions. To test whether released Zn2+ ions might account for the difference, the bacteria-phanorod-Zn
complexes were centrifuged and washed in PBS buffer three times after
irradiation, to remove Zn2+ ions. Washing the bacteria-phanorod-Zn
complexes resulted in lower antibacterial efficiency (86.1 ±
4.2% cell death) compared with intact phanorod-Zn (97.5 ± 1.5%; p < 0.001) and was comparable to the efficiency of phanorods
(Figure c). This result
supported the interpretation that released Zn2+ ions improved
antibacterial efficiency by ∼10%, for phanorod-Zn compared
to phanorods.[54]Because nonspecific
effects may occur due to bulk heating of the
suspension, we tested the specificity of bacteriocidal activity of
phanorods and phanorod-Zn by incubation with E. coli and Vibrio cholerae (Figure S8). Some reduction (∼20%) in cfu was observed, but
survival of these species was substantially greater than that observed
for P. aeruginosa. The difference in bacteriocidal
efficiency is consistent with the engineered specificity of the phage
M13-g3p(Pf1).[24] A similar degree of nonspecific
cell-killing was also observed with AuNRs alone under the same conditions
(Figure S15b).
Antibacterial Activity
of Phanorod-Zn with P. aeruginosa Biofilms In Vitro
P. aeruginosa is known
to produce robust biofilms, leading to persistent infections and increased
antimicrobial resistance.[55,56]P. aeruginosa biofilms were grown in vitro and exposed to phanorods and phanorod-Zn.
Consistent with the results from planktonic culture, the antibacterial
efficiency for P. aeruginosa biofilm eradication
by phanorod-Zn was significantly higher (94.2 ± 1.7%) than for
phanorods (86.5 ± 3.6%, P < 0.01) (Figure d). Consistent with
this, live/dead staining of the biofilm showed significantly greater
dead cells (97.6 ± 1.3%) with phanorod-Zn compared to phanorods
(84.7 ± 1.5% dead cells; p < 0.0001) (Figures S9 and S10). These studies verified that
phanorod-Zn was ∼10–13% more effective than phanorods
in the biofilm, quantitatively consistent with the results obtained
for planktonic culture. To determine whether the cell-killing was
effective deeper into the biofilm, confocal image slices of the live/dead
staining were used to reconstruct a three-dimensional image, which
showed efficient cell-killing throughout the biofilm under these conditions
(Figure S11a,b).
Antibacterial Activity
of Antibody-AuNRs with P. aeruginosa In Vitro
For comparison to phanorods and phanorod-Zn, AuNRs
were also conjugated to a monoclonal antibody (1010/287) that recognizes P. aeruginosa serotype 6 (ATCC25102 (Schroeter) Migula).[24,57,58] Photothermal properties and absorbance
spectra of antibody-AuNRs were confirmed to be similar to phanorods
and phanorod-Zn (Figure S1g,h). Binding
of the antibody-AuNRs to P. aeruginosa cells was
confirmed by TEM, which showed antibody-AuNRs bound to the surfaces
of P. aeruginosa cells, with ∼50 antibody-AuNRs
per cell (Figure S5d,e). As expected, free
AuNRs did not associate with P. aeruginosa cells.
The antibacterial efficiency of antibody-AuNRs was measured using
a particle suspension containing the same concentration of Au as the
phanorod and phanorod-Zn suspensions. In suspension, cell-killing
was less efficient with antibody-AuNRs compared to phanorods and phanorod-Zn
(70–80% cell death; Figures S12a and S13b) and even lower in a biofilm (55–65% cell death; Figures S11c, S12b, and S14b).
Comparison
of Antibacterial Effect of Phanorod-Zn, Phanorods
with Free Zn2+, and AuNR-Pol-K In Vitro
The results
above showed that the antibacterial efficiency of phanorod-Zn was
∼10% higher than that of phanorods in vitro. In addition, if
released Zn2+ ions were removed by centrifugation and washing,
the antibacterial efficiency of phanorod-Zn dropped to that of phanorods,
suggesting that the released Zn2+ improved the antimicrobial
efficiency. To understand whether these two components, phanorods
and Zn2+, interacted additively or synergistically with
each other to produce the antibacterial effect of phanorod-Zn, we
compared phanorod-Zn to an equivalent preparation of phanorods mixed
with free Zn2+. The concentration of Zn2+ released
after one irradiation in vitro was measured to be 1.06 ppm (16.2 μM)
at 24 h (Figure a).
Alone, Zn2+ of this concentration showed insignificant
bacterial killing (Figure S15b). Phanorods
were compared to a mixture of phanorods and Zn2+ (1.06
ppm, 16.2 μM). No significant difference was seen in cell-killing
rates of the phanorods (4.5 ± 2.2%) compared to phanorods mixed
with Zn2+ (6.3 ± 2.8%; p > 0.05),
given irradiation achieving low temperature (45 °C; Figure S15a). However, at higher laser flux achieving
higher temperature, the cell-killing rates of both groups increased,
with the phanorods mixed with Zn2+ being significantly
more effective than phanorods alone (at 55 °C: 87.5 ± 1.8%
cell-killing by phanorods and 94.5 ± 1.1% cell-killing by phanorods
mixed with Zn2+; p < 0.001) (Figure S15a). Nevertheless, phanorod-Zn (97.5
± 1.5%) was still significantly more effective compared to phanorods
mixed with Zn2+ (p < 0.001), indicating
that phanorods and Zn2+ interact synergistically to augment
bacteriocidal activity in phanorod-Zn.To assess the importance
of targeting the bioconjugates to the host cells, we conjugated AuNRs
to Pol-K and loaded them with Zn2+. These bioconjugates
would release Zn2+ upon photothermal heating, but lack
binding activity for the bacterial cells. The Zn2+-loaded
AuNR-Pol-K shows significantly lower antimicrobial efficiency than
phanorod-Zn (p < 0.001; Figure S15b; Figure b), illustrating the importance of targeting using phage.
In Vitro
Cytocompatibility of Phanorods, Phanorod-Zn, and Zn2+
The in vitro cytocompatibility of the phanorods
and phanorod-Zn with mammalian cells was studied by the PrestoBlue
cell viability assay using human embryonic kidney (HEK) 293T cells.
The results (Figure S15c) indicate that
the bioconjugates are nontoxic to the HEK293T cells, with cell viabilities
above 98% for all concentrations tested (up to 0.4 μM Au). For
free Zn2+ (Figure S15d), low
concentrations (2 ppm or 31 μM and below) were found to be nontoxic
to the HEK293T cells, with cell viability of >98%. However, cell
viability
was substantially decreased at [Zn2+] higher than 6 ppm
(92 μM). The maximum cumulative Zn2+ concentration
released by phanorod-Zn is 1.69 ppm or 25.9 μM (Figure ), given laser irradiation
for 15 min every 24 h, for 72 h. Zn2+ at this concentration
(1.69 ppm, 25.9 μM) displays insignificant cytotoxicity toward
HEK293T cells, indicating that the amount of Zn2+ released
during phanorod-Zn treatment would not decrease the viability of these
cells.
Treatment of P. aeruginosa-Infected Wounds
by Phanorods and Phanorod-Zn In Vivo
We evaluated the in
vivo efficacy of phanorods and phanorod-Zn for treatment of P. aeruginosa-infected wounds using a mouse model. Wounds
were introduced dorsally by scissors on anesthetized mice and inoculated
with P. aeruginosa (1 × 107 cfu).
For initial experiments, after incubation for 1 h, phanorods or phanorod-Zn
were applied topically to the wound, incubated for 30 min, and activated
by exposure to NIR irradiation for 15 min (808 nm, 0.3–4 W
cm–2). Mice were monitored by thermal imaging to
measure the temperature of the wound during treatment. Higher laser
intensity (0.35–4 W cm–2) caused heating
beyond 55 °C, resulting in a burn characterized by macroscopic
discoloration, inflammation, and neutrophil infiltration (Figure S16). While the higher laser intensities
resulted in high bacterial cell-killing rate (91.3 ± 2.1% cell
death at 60 °C; 94.4 ± 1.1% cell death at 65 °C), a
moderate laser intensity (0.3 W cm–2), causing heating
to 55 °C, gave a similar cell-killing rate (90.7 ± 1.2%)
(Figure S17) and relatively little tissue
damage. This intensity (0.3 W cm–2) is also within
the scope of permissible skin exposure formulated by the American
National Standards Institute (ANSI Z136.1-2000).[59] Therefore, heating to 55 °C at this laser intensity
for 15 min was chosen as the appropriate condition for subsequent
experiments.Wounds were created and infected on day 0. In the
control group (wound exposed to PBS buffer; untreated), the wound
temperature did not change observably under laser irradiation (Figure a). On day 2, macroscopic
suppuration and inflammation were observed in the wounds of the control
group, and the wound area had approximately doubled from the initial
size (Figure b,c).
Subsequently, the untreated wounds decreased slowly in size, reaching
the original wound size on day 8, but were not closed by day 10. When
treated with an equivalent amount of free Zn2+ (1.06 ppm,
16.2 μM) on days 1 and 2, the wound area increased in size similar
to the control group (Figure , S19b), as expected since this
concentration of Zn2+ is known to be too low to prevent
the formation of biofilms by most pathogenic bacteria.[60]
Figure 3
Treatment of P. aeruginosa-infected wounds
by
phanorod-Zn in vivo. (a) Thermal images of control and phanorod-Zn
treatment before and after the NIR laser irradiation. (b) Representative
photographs of the infected wound over time for control, Zn2+ ion, phanorod, and phanorod-Zn treatment (scale bar = 5 mm). (c)
Wound area over time for control, phanorod, and phanorod-Zn treatment.
Also see Figure S19. (d) Bacterial load
assessed by cfu from wound tissue on days 2 and 4. Error bars show
standard deviation (n = 5 mice): *** indicates p < 0.001; NS = not significant (p >
0.05); two-sided t test.
Treatment of P. aeruginosa-infected wounds
by
phanorod-Zn in vivo. (a) Thermal images of control and phanorod-Zn
treatment before and after the NIR laser irradiation. (b) Representative
photographs of the infected wound over time for control, Zn2+ ion, phanorod, and phanorod-Zn treatment (scale bar = 5 mm). (c)
Wound area over time for control, phanorod, and phanorod-Zn treatment.
Also see Figure S19. (d) Bacterial load
assessed by cfu from wound tissue on days 2 and 4. Error bars show
standard deviation (n = 5 mice): *** indicates p < 0.001; NS = not significant (p >
0.05); two-sided t test.With phanorod and phanorod-Zn treatment (day 0: reagent applied
and incubated for 30 min, after wound inoculation, and irradiated
for 15 min; day 1: irradiated again for 15 min), the wound temperature
rapidly increased to ∼55 °C in 2–3 min during laser
irradiation (Figures a and S18). With phanorod and phanorod-Zn
treatment, wound size did not increase and instead decreased markedly
over the next several days; by day 4, the wound area with treatment
was <20% of the area of an untreated wound. Macroscopic signs of
inflammation were minimal, and the wound reached complete closure
by day 8. Assessment of bacterial load by cfu in the wound tissue
confirmed that the decrease in wound size corresponded to a decrease
in cfu by >10-fold by day 2 and >100-fold by day 4, relative
to the
control (Figure d).
With phanorod treatment, a similar trend was observed, although healing
and cfu decrease appeared slightly less rapid compared to phanorod-Zn
(Figure c,d). A close
comparison of the wound areas of the two groups on different days
revealed that phanorod-Zn showed a significantly better therapeutic
effect than the phanorods (Figure S19a).Treatment with phage M13-g3p(Pf1) or unconjugated AuNRs gave results
similar to the negative control by wound size and bacterial load (Figure S20), indicating that only the bioconjugated
reagents were active. Interestingly, phanorod or phanorod-Zn treatment
resulted in a wound closure rate that was slightly faster than that
of noninfected wounds (i.e., had not been inoculated with P. aeruginosa), suggesting that hyperthermia and/or Zn2+-release may be slightly beneficial even in the absence of
overt infection (Figure S21).[61,62] The reason for this slight benefit is unclear; because the mice
were not kept in a sterile environment, it is possible that wounds
that were not inoculated nevertheless harbored a small population
of bacteria, and treatment reduced the burden of these cells. In addition,
local heating might increase lymphocyte extravasation,[63] blood flow, and oxygen tension,[64] which may be beneficial to the innate immune response.Phanorod-Zn treatment with a single irradiation was also assessed
(irradiation only on day 0). The single irradiation regimen was also
effective, with a wound closure rate comparable to a noninfected wound,
but was less effective than irradiation on two consecutive days (Figure S21). The difference is consistent with
the fact that a small percentage of bacteria survive a single irradiation
treatment (Figure d) and that additional Zn2+ is released upon the second
treatment (Figure b). Overall, these results indicated that phanorod-Zn, and phanorods
to a slightly lesser extent, were highly effective for reducing bacterial
load and accelerating wound healing in the mouse model.
Comparison
of Phanorod-Zn Treatment to Standard Antibiotic Therapy
In Vivo
To compare the efficacy of phanorod-Zn treatment
to standard therapy, multiple antibiotic and antiseptic treatments
were assessed in the same wound infection model. Treatments included
two topical antiseptic agents (acetic acid (2% solution) and chlorhexidine
(4% solution)), a topical antibiotic (polysporin) ointment, and two
systemic antibiotics (oral ciprofloxacin and levofloxacin). While
all treatments were effective in promoting wound closure faster than
no treatment, phanorod-Zn treatment gave significantly faster wound
closure, accompanied by ∼10-fold greater reduction in bacterial
load (Figures and S22). While wound closure was completed with
phanorod-Zn treatment by day 8, none of the other treatments yielded
wound closure by day 10. These results indicated that phanorod-Zn
treatment was more effective than standard antimicrobial therapies
in the mouse model.
Figure 4
Treatment of infected wounds assessed by wound size (a)
over time,
comparing antibiotics (ciprofloxacin, levofloxacin, polysporin) and
antiseptics (acetic acid, chlorhexidine) with phanorod-Zn. Treatment
was initiated on day 0 in all cases. (b) Quantitative assessment of
bacterial load (cfu) in wounds during wound treatment. Error bars
show standard deviation (n = 5 mice): *** indicates p < 0.001 (two-sided t test).
Treatment of infected wounds assessed by wound size (a)
over time,
comparing antibiotics (ciprofloxacin, levofloxacin, polysporin) and
antiseptics (acetic acid, chlorhexidine) with phanorod-Zn. Treatment
was initiated on day 0 in all cases. (b) Quantitative assessment of
bacterial load (cfu) in wounds during wound treatment. Error bars
show standard deviation (n = 5 mice): *** indicates p < 0.001 (two-sided t test).
Efficacy of Delayed Phanorod-Zn Treatment
In Vivo
In
initial experiments, treatments (including phanorod-Zn and antibiotic
therapy) were initiated on day 0, shortly after wound creation and
inoculation with P. aeruginosa. To determine whether
the same treatments were effective late into infection, we tested
the effect of treatments initiated once the wounds reached maximum
size (day 2). When treatment was delayed, ciprofloxacin treatment
was observed to have a minor effect, if any, on the rate of wound
closure or bacterial load compared to no treatment (Figures and S23), consistent with formation of a biofilm during the 2 days without
treatment. However, with phanorod-Zn treatment beginning on day 2
(with a second round of irradiation performed on day 3), wound size
decreased rapidly after day 2, and wound closure was complete on day
10. Unlike delayed ciprofloxacin treatment, the bacterial load after
delayed phanorod-Zn treatment decreased markedly, consistent with
the observed decrease in wound size (Figure ). These results indicated that, when wound
treatment was delayed, phanorod-Zn treatment was still effective,
in contrast to ciprofloxacin treatment.
Figure 5
Delayed treatment of
infected wounds, with treatment initiated
at maximum wound size (day 2). (a) Wound size over time, with either
ciprofloxacin or phanorod-Zn treatment begun on day 2. Control = no
treatment. (b) Quantitative assessment of bacterial load (cfu) with
treatment begun on day 2 and assessed on days 2, 4, and 6. Samples
on day 2 were taken without treatment. Error bars show standard deviation
(n = 5 mice): * indicates p <
0.05, *** indicates p < 0.001, NS = not significant
(p > 0.05); two-sided t test.
Delayed treatment of
infected wounds, with treatment initiated
at maximum wound size (day 2). (a) Wound size over time, with either
ciprofloxacin or phanorod-Zn treatment begun on day 2. Control = no
treatment. (b) Quantitative assessment of bacterial load (cfu) with
treatment begun on day 2 and assessed on days 2, 4, and 6. Samples
on day 2 were taken without treatment. Error bars show standard deviation
(n = 5 mice): * indicates p <
0.05, *** indicates p < 0.001, NS = not significant
(p > 0.05); two-sided t test.
Efficacy of Phanorod-Zn Treatment for Severe
Wounds In Vivo
The wounds described above in this study (initially
∼8 mm2, infected by 1 × 107 cfu)
were small enough
to eventually heal without intervention. While these wounds allowed
quantitative comparisons of size and cfu over time, wounds of larger
size (∼17 mm2) with greater bacterial inoculum (5
× 107 cfu) were also studied to assess treatment of
severe cases. For these severe wounds, the control wounds (no treatment:
exposure to PBS) showed a mortality rate of 100% (5 out of 5 mice)
within 3 days (Figures and S24). However, all mice with severe
wounds treated with phanorod-Zn survived (5 out of 5 mice), with wound
closure by 10–12 days. Interestingly, even when phanorod-Zn
treatment was delayed (initiated on day 2 with second round of irradiation
on day 3), all mice survived the severe wounds (5 out of 5 mice),
and wound closure was complete by 12–14 days. These results
indicate that phanorod-Zn treatment, even if delayed, was effective
for rescuing mice from severe wounds that would otherwise result in
100% mortality.
Figure 6
Treatment of severe wound infections by phanorod-Zn, initiated
early (L0 + L1) or delayed initiation on day 2 (L2 + L3). (a) Wound
size over time; no data is available for the control group (no treatment)
past day 2 due to 100% mortality. (b) Quantitative assessment of bacterial
load (cfu) during treatment of severe wound infections, measured on
days 2, 4, and 6. For delayed treatment (L2 + L3), samples on day
2 were taken without treatment. Error bars show standard deviation
(n = 5 mice): *** indicates p <
0.001 (two-sided t test).
Treatment of severe wound infections by phanorod-Zn, initiated
early (L0 + L1) or delayed initiation on day 2 (L2 + L3). (a) Wound
size over time; no data is available for the control group (no treatment)
past day 2 due to 100% mortality. (b) Quantitative assessment of bacterial
load (cfu) during treatment of severe wound infections, measured on
days 2, 4, and 6. For delayed treatment (L2 + L3), samples on day
2 were taken without treatment. Error bars show standard deviation
(n = 5 mice): *** indicates p <
0.001 (two-sided t test).
Treatment of Polymyxin-Resistant P. aeruginosa with
Phanorod-Zn In Vivo
The main application of an alternative
antimicrobial class is anticipated to be treatment of antibiotic-resistant
infections. Current last-line therapy for P. aeruginosa is polymyxin antibiotics. We tested phanorod-Zn treatment of wounds
infected by a polymyxin-resistant strain of P. aeruginosa, PAKpmrB6.[65,66] Consistent with this
phenotype, polymyxin treatment was ineffective against wounds infected
by strain PAKpmrB6, while phanorod-Zn treatment was
effective, as shown by decreased wound size and decreased bacterial
load (Figures and S25). Phanorod-Zn treatment delayed to the time
of maximum wound size (initiated on day 2) was also effective with
this strain (Figure ). These results confirm that phanorod-Zn treatment is effective
against wound infection by an organism resistant to last-line therapy.
Figure 7
Treatment
of wounds infected by polymyxin-resistant P.
aeruginosa. (a) Wounds assessed by size over time, with polymyxin
treatment initiated on day 0 or phanorod-Zn treatment initiated on
day 0 (L0 + L1) or day 2 (L2 + L3). (b) Quantitative assessment of
bacterial load (cfu) for polymyxin-resistant P. aeruginosa wound infection, measured on days 2, 4, and 6. For delayed treatment
(L2 + L3), samples on day 2 were taken without treatment. Error bars
show standard deviation (n = 5 mice): *** indicates p < 0.001; NS = not significant (p >
0.05); two-sided t test.
Treatment
of wounds infected by polymyxin-resistant P.
aeruginosa. (a) Wounds assessed by size over time, with polymyxin
treatment initiated on day 0 or phanorod-Zn treatment initiated on
day 0 (L0 + L1) or day 2 (L2 + L3). (b) Quantitative assessment of
bacterial load (cfu) for polymyxin-resistant P. aeruginosa wound infection, measured on days 2, 4, and 6. For delayed treatment
(L2 + L3), samples on day 2 were taken without treatment. Error bars
show standard deviation (n = 5 mice): *** indicates p < 0.001; NS = not significant (p >
0.05); two-sided t test.
Comparison of Phanorod-Zn with Antibody-AuNRs In Vivo
Treatments
by AuNRs conjugated to antibodies (rather than phages)
were studied, in order to determine whether phages possessed any advantage
over antibodies for targeting bacterial cells. A monoclonal antibody
(1010/287) recognizing the P. aeruginosa strain used
here (PAK, serotype 6) was conjugated to AuNRs and tested for treatment
of P. aeruginosa-infected wounds (Figure S20). The antibody-AuNRs were less effective than phanorod-Zn,
but gave comparable results to treatment by antibiotics, as shown
by the reduction in wound size and bacterial load (Figure S20). Thus, while treatment by antibody-AuNRs was inferior
to phanorod-Zn, their moderate efficacy validated the general approach
of using an affinity reagent to target AuNRs toward the bacterial
cells for photothermal treatment. Although antibody-AuNRs were less
effective than phanorod-Zn, antibody-AuNRs were more effective than
Zn2+-loaded AuNR-Pol-K, confirming the primary importance
of targeting therapeutic agents to the pathogens in antibacterial
treatment.
Histological Analysis and Collagen Deposition
during Phanorod-Zn
Treatment In Vivo
When infected wounds were not treated (exposed
to PBS buffer), a high degree of neutrophil infiltration into the
wound tissue was observed by hematoxylin and eosin (H&E) staining
on day 2 (Figure ),
consistent with acute inflammation and infection. In the control group,
neutrophil infiltration is still observed on day 6, indicating prolonged
inflammation, consistent with macroscopic signs of inflammation (redness
and swelling) seen in the wound photographs for the untreated control
group. In comparison, neutrophil infiltration in the phanorod and
phanorod-Zn treatment groups was less dense on day 2 and decreased
considerably in the following days (Figures and S26), consistent
with a resolving infection.
Figure 8
H&E staining of wound tissue sections on
days 2, 6, and 10.
First column: control (no treatment); second column: phanorod treatment;
third column: phanorod-Zn treatment. Treatments were initiated on
day 0. Scale bar = 50 μm. Neutrophil infiltration is pronounced
in the control.
H&E staining of wound tissue sections on
days 2, 6, and 10.
First column: control (no treatment); second column: phanorod treatment;
third column: phanorod-Zn treatment. Treatments were initiated on
day 0. Scale bar = 50 μm. Neutrophil infiltration is pronounced
in the control.To assess wound repair at a microscopic
level, we used Masson’s
trichrome staining to monitor collagen deposition in the wounds. Phanorod-Zn
treatment resulted in substantially greater collagen deposition than
the untreated control throughout the wound healing time frame (Figure S27). Interestingly, phanorod-Zn treatment
also gave greater collagen deposition compared to phanorod treatment,
indicating that Zn2+ release from phanorod-Zn was beneficial
for wound healing. Quantitation of collagen area from Masson’s
trichrome staining indicated ∼89.4 ± 5.6% collagen coverage
of wound tissue sections by day 8 for phanorod-Zn treatment, consistent
with wound closure by this day, which was significantly greater than
collagen coverage from phanorod treatment (∼54.8 ± 6.5%, p < 0.001), which in turn was significantly greater than
collagen coverage with no treatment (∼30.9 ± 2.2%, p < 0.001) by day 8 (Figure S28). Therefore, phanorod-Zn treatment was associated with reduced inflammation
and relatively rapid collagen deposition, consistent with accelerated
wound healing.
Toxicity Profile of Phanorods and Phanorod-Zn
In Vivo
To evaluate possible systemic toxicity of phanorod
and phanorod-Zn
treatment, major organs (liver, spleen, kidneys, heart, and lungs)
were harvested on day 10 and analyzed by H&E staining. No differences
were apparent among the untreated, phanorod treatment, and phanorod-Zn
treatment groups (Figure S29), showing
no histological indication of toxicity. Hematological analysis (hematocrit
(HCT), hemoglobin (HGB), mean corpuscular HGB concentration (MCHC),
mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV),
platelet count, red blood cell count (RBC), red cell distribution
width, and white blood cell count (WBC)) also showed no significant
differences among levels in the untreated, phanorod, and phanorod-Zn
groups at day 10 (Figure S30a).To
study hepatic and renal toxicity in particular, the biomarkers alkaline
phosphatase (ALP), alanine transaminase (ALT), aspartate transaminase
(AST), blood urea nitrogen (BUN), creatinine, and uric acid were also
assessed on day 10. No significant differences were seen for the phanorod
and phanorod-Zn treatment groups compared to the untreated group (Figures S30–S32). In contrast, fluoroquinolone
and polymyxin treatments resulted in significant elevations, consistent
with the known toxicity of these antibiotics.To test whether
phanorod and phanorod-Zn treatment resulted in
elevated levels of systemic Au2+ or Zn2+, the
blood concentrations of these ions were measured. Au2+ concentrations
were undetectable in all groups (limit of detection = 0.002 ng/mL).
The serum concentration of Zn2+ ions was slightly elevated
in the phanorod-Zn group compared to the phanorod and untreated groups,
but the difference was not statistically significant (Figure S30b). Overall, phanorod and phanorod-Zn
treatments did not show signs of systemic toxicity, as assessed after
wound closure.
Tissue Biodistribution of Phanorods and Phanorod-Zn
To study the biodistribution of phanorods and phanorod-Zn in mice,
the concentration of the bioconjugate in the major organs and wound
skin was investigated on day 8 following wound infection and treatment,
measured by ICP-MS for Au (Supporting Methods). The concentration of Au was >10-fold higher in the wound skin
compared to all other organs measured (liver, kidneys, spleen, lungs,
or heart) (Figure S33). Among these organs,
the liver and spleen showed a higher Au amount compared to other organs.
This is consistent with the topical application and washing of the
bioconjugates during treatment and is in accordance with previous
studies in biodistributions of nanoparticles for topical wound healing
applications.[67,68]
Conclusions
Phage
therapy is usually envisioned with lytic phages that self-amplify
exponentially to eradicate a bacterial population. However, such a
strategy poses multiple concerns about safety and efficacy, particularly
if using poorly characterized phages. Yet phages have evolved multiple
mechanisms for discovering and attaching to bacterial hosts in natural
environments, including receptor-binding proteins whose affinities
rival or surpass those of antibodies and subdiffusive “search”
mechanisms.[69−73] By using chimeric M13 phages to carry an activatable, toxic cargo
to bacterial pathogens, the phanorod strategy takes advantage of phage
attachment while controlling the antimicrobial effect. Unlike phage
therapy, the phage component of phanorods does not need to infect
or lyse the host cells, limiting the requisite genetic engineering
to the receptor-binding interaction, in contrast to strategies that
rely on phage infection and gene expression.[74] Such engineering to bind different host bacterial strains can be
achieved by creating chimeric phages, in which the receptor-binding
protein of M13 has been replaced by the homologue from a filamentous
phage that targets the pathogen; the chimeric phages bind and deliver
cargo to the targeted pathogen.[20] At the
same time, complete phages may be advantageous over phage proteins
(e.g., lysins[75]) for robustness to exposure
to serum and the physiological milieu.[22,76] M13 and Pf1
are nonlytic filamentous phages (inoviruses), which bind to specific
bacterial pili. In particular, the receptor-binding domain of Pf1
(used in the M13-g3p(Pf1) phanorods) binds to type IV pili, a virulence
factor that enables adhesion, motility, and biofilm formation.[77] In one analysis, 75% of P. aeruginosa strains isolated from wound infections expressed type IV pili.[78] Therefore, filamentous phages may be an appropriate
source of receptor-binding domains against pathogens.The advantage
of phage-based targeting of AuNRs was highlighted
in vivo. An alternative to phage targeting is antibody targeting,
which is under study for antibacterial applications.[79−81] Using an anti-P. aeruginosa monoclonal antibody
with irradiation intensity tuned to achieve the same wound temperatures,
reduction of the wound size to <50% of the initial size required
>6 days with antibody-AuNR treatment, but only 2 days with phanorod
treatment (Figure S20). This difference
could be due to the greater cargo capacity of phanorods, which carry
approximately 15 AuNRs per particle,[24] compared
to antibodies, whose size (∼12 nm) is unlikely to accommodate
more than one AuNR (∼14 × 53 nm) per molecule. Even if
a similar number of AuNRs attaches per cell when antibody targeting
is used (e.g., with the antibody targeting a highly abundant bacterial
receptor compared to pili), activation of multiple AuNRs at the same
microscopic location, targeted by phanorods, would create a steeper
thermal gradient at that site, compared to activation of the same
number of AuNRs spaced apart from one another (Figure S5). TEM images also suggested that phanorods may aggregate
together on the bacterial surface, possibly due to multiple interactions,
which would further amplify the steepness of the gradient. In addition,
phages are more stable than antibodies under harsh chemical conditions
and high temperatures.[76,82] This latter property may be relevant
to the studies here, as early denaturation of the molecular interactions
during photothermal heating could lead to dissociation of the bioconjugate
from the bacterial cell. Also, while attachment of antibody-AuNRs
was verified by TEM in this case, in principle, nonspecific conjugation
of AuNRs might be more likely to interfere sterically with the antibody–antigen
interaction due to their relative sizes, compared to the phage-receptor
interaction, which occurs at one end of the virion (∼9 nm diameter
×1 μm length). Understanding the mechanisms for the advantage
of phage- over antibody-targeting would require further study.While the quantitatively increased efficacy of phanorods over antibody-nanorods
is important for individual treatment, it could also be significant
at a population level, as under-treatment of microbial infections
can lead to development of resistant phenotypes and strains as well
as poorer clinical outcomes.[83−86] Indeed, resistant strains of P. aeruginosa emerge in ∼10% of cases during antibiotic treatment,[87] suggesting that high efficacy is a critical
feature for new therapeutic agents. Furthermore, the ability to engineer
or evolve phages to overcome bacterial resistance is an important
future concern. For the photothermal mechanism described here, resistance
mechanisms are presumably limited to disruption of the receptor-binding
interaction. A perceived advantage of phage therapy is the potential
to conduct directed evolution to overcome bacterial resistance;[88] given the evolvability of phages against new
receptors observed in other studies,[89−92] such future developments may
be feasible.A well-known problem for antibiotics is penetration
through biofilms,
as illustrated by the relative lack of efficacy of ciprofloxacin treatment
in the mice after the wound infection was left untreated for 2 days.
Although we did not measure distribution of the phanorods into the
biofilm, the cell-killing effect did not appear to be impeded by a
biofilm in vitro, to the depth observed (∼9 μm). It should
be noted that regardless of whether phanorods themselves penetrate
the biofilm, the cytotoxic effect is mediated by the thermal gradient.
Since biofilms may be ∼80–95% water,[93,94] thermal conductivity is likely to be similar to that of water. The
excellent efficacy of phanorods and phanorod-Zn in vivo, particularly
when treatment was delayed for 2 days, also confirmed that the biofilm
developed in the wounds of these experiments did not prevent treatment.An important practical question for phanorod and phanorod-Zn treatment
was whether the bacterial population could be effectively eradicated
without excessive harm to the animal, either locally or systemically.
Greater laser exposure would result in greater bacterial cell-killing,
but would also increase the potential for negative side effects from
thermal burn at the wound area. Optimization experiments indicated
that burns could be minimized by adjusting laser intensity to achieve
a certain steady-state temperature (∼55 °C), while maintaining
excellent bacteriocidal activity. Another source of potential harm
is renal or hepatic toxicity, which limits the use of some antibiotics.
For example, current last-line antibiotic treatment for P.
aeruginosa and other Gram-negative infections is polymyxins,
a drug class with substantial renal toxicity; in one study, 2/3 of
patients treated by colistin developed nephrotoxicity marked by elevated
creatinine levels.[95] In our experiments,
indicators of renal and hepatic function indicated compromise after
treatment of infected mice by systemic fluoroquinolones and polymyxin
antibiotics, as expected. However, no elevations were seen after treatment
with phanorods or phanorod-Zn. The lack of systemic toxicity is consistent
with the localized application, in which the phanorods or phanorod-Zn
were applied and incubated briefly to allow binding to target bacteria
before irradiation. The biodistribution assessed here (day 8) showed
that relatively little Au was present in organs other than the wound
skin itself, consistent with other studies on the biodistribution
of nanoparticles in topical wound healing applications.[67,68] However, more work would be needed to assess biodistribution and
biosafety over longer time periods. Another concern was whether phanorods
or phanorod-Zn might induce a dysfunctional immune response. However,
no significant elevation was seen in the white cell count. Other blood
cell counts were also statistically indistinguishable from the untreated
control, illustrating a lack of measured systemic toxicity.Phanorod-Zn was designed to be loaded with Zn2+ that
could be released upon photothermal heating. In this case, the Zn2+-binding peptide Pol-K was conjugated through EDC chemistry.
An alternative approach could be designing a fusion of Pol-K with
g8p, although proper phage assembly would require verification when
engineering the major coat protein. In these experiments, a temperature
change was shown to cause Zn2+ release. Similarly, systems
such as zinc fingers[47] and Zn2+-substituted rubredoxins[46] are reported
to release metal ions like Zn2+ upon thermal denaturation.
Irradiation also resulted in a decrease in thiol groups. The amount
of thiol loss apparently did not reduce the Zn2+-loading
capacity in this system, possibly because some of the lost thiols
were not from Pol-K, and the four thiols of Pol-K may not all be necessary
for coordination.[96] However, binding affinity
is reduced as the number of coordinating cysteines decreases.[96] Here, both the effects of increased temperature
and loss of thiols may contribute to the observed photothermal release
of Zn2+. Higher levels of thiol destruction may also affect
loading capacity and lead to greater release of Zn2+. While
Zn2+ is an important trace metal for bacterial growth when
present at low concentrations, higher concentrations are inhibitory,
due to competition for metal-binding sites in proteins as well as
direct association with bacterial cell membranes, leading to rupture.[97] Furthermore, increased concentrations of Zn2+ may lead to oxidative stress that can damage bacterial membranes,
DNA, and mitochondria, resulting in bacterial death.[98] Indeed, phanorod-Zn was more effective at cell-killing
compared to phanorods in our experiments, particularly in vitro, which
appeared to be due to a released solute (presumed Zn2+).
At the same time, Zn2+ is relatively well-tolerated in
humans,[99] and zinc oxide, in particular,
has been shown to cause improvement in wound healing in multiple animal
and clinical studies.[38] Zinc is reported
to be involved in regulating several phases of the wound healing process,
including membrane repair, oxidative stress, coagulation, inflammation
and immune defense, tissue re-epithelialization, angiogenesis, and
fibrosis formation.[100] Although still unclear,
release of Zn2+ is believed to be one of the mechanisms
by which zinc oxide affects wound healing. Zn2+ is favorable
for deposition of collagen, an essential component of tissue repair.[101−103] Indeed, our studies suggested greater collagen deposition after
phanorod-Zn treatment (48.3 ± 4.6%, day 2; 61.3 ± 5.7%,
day 4) compared to phanorod treatment (18.6 ± 3.7%, day 2; 30.5
± 5.2%, day 4), although it should be noted that the long-term
effect of this deposition is unknown. In vivo, phanorod-Zn treatment
appeared to be slightly more effective than phanorods in terms of
wound reduction and cfu reduction, but these differences were not
always statistically significant; more work is needed to clarify the
overall effect of zinc release in this system.The TEM images
and prior microscopy with molecular rotors[37] indicate that photothermal activation of phanorods
and phanorod-Zn causes severe damage to bacterial cells and membranes,
such that cellular structures were no longer intact. Zn2+ is a micronutrient, but at high concentrations, Zn2+ is
toxic to bacteria,[104−106] although the molecular basis of toxicity
remains poorly understood. Very high concentrations of Zn2+ (336 ppm, 5.14 mM) significantly alter membrane permeability of
bacterial cells and result in cell death.[107] A plausible mechanism for the observed synergistic interaction of
phanorods with Zn2+, resulting in increased toxicity of
phanorod-Zn compared to a mixture of phanorods and free Zn2+, may be that localized photothermal heating disrupts the cell membrane,
allowing the released Zn2+ ions to penetrate the cells.
Nevertheless, photothermal ablation appears to be the dominant mechanism
of toxicity, given the high efficacy of phanorods alone. Aside from
toxicity, another property of phanorod-Zn appears to be improved wound
healing compared to phanorods, as suggested by greater collagen deposition
and significantly faster decrease in wound size. This difference is
also consistent with the release Zn2+ ions, which are known
to be associated with improved wound healing.[38,108]In this work, we validated phanorods and phanorod-Zn as a
potential
antimicrobial treatment in a mouse model of P. aeruginosa wound infection (Table S1). The work
presented here combines multiple strategies to create a nanomaterial
that differs from prior approaches in several aspects. Each M13 phage
particle can carry at least 1 order of magnitude more cargo compared
with biomolecular targeting materials (e.g., antibodies), leading
to more efficient cell ablation. In addition, the M13 phage appears
to be very robust in capturing the bacterial target, even in harsh
or complex environments (e.g., in vivo), possibly owing to the ongoing,
long-term coevolutionary arms race between phages and bacteria.[76] Interesting, the antibacterial effects of the
photothermal AuNRs and the released Zn2+ ions were found
to be synergistic, killing the bacteria at relatively low local temperatures,
which would be advantageous for protecting the surrounding tissues.
Furthermore, the released Zn2+ can also accelerate wound
tissue repair and promote collagen deposition. Considering utilization
in practice, application of phanorods and phanorod-Zn is likely to
be less convenient than orally administered antibiotics since treatment
must be rendered in person. However, the primary importance of emerging
therapies such as these would be for situations in which standard
antibiotics have already failed. The in-person treatment time (approximately
1 h) would be comparable to intravenously administered antibiotics
and only needs to be rendered 1–2 times (compared to a several-day
course of intravenous antibiotics). Our study also shows that the
practical challenges of treatment in vivo, such as monitoring wound
temperature and mitigating laser power, can be surmounted. In addition,
toxicity was not detected for the treatment regimen used, consistent
with the surface application. An important consideration for future
application is whether phanorods can be engineered to target particular
pathogens. In general, phages, which determine specificity in this
system, may be highly specific or have relatively broad host range.[109] Since phanorods rely only on attachment, expression
of the appropriate receptor is expected to be the major, and possibly
the sole, requirement for bacterial susceptibility. Some receptors,
such as virulence factors, may be expressed by a substantial fraction
of pathogens; further work is needed to define the frequency of targetable
receptors in pathogenic populations. Given a susceptible organism,
phanorod or phanorod-Zn treatment may be advantageous in terms of
efficacy compared to standard-of-care antibiotic therapy. This was
demonstrated in this study by the 3× faster rate of healing (Figure ), in which phanorod-Zn
treatment led to a 50% reduction in wound size by day 2, a level that
was achieved by systemic ciprofloxacin only on day 6. In addition,
phanorod-Zn showed an important lack of effect on hepatic and renal
biomarkers (Figure S32), compared to systemic
fluoroquinolones, whose toxicity resulted in significantly elevated
biomarker levels. These advantages may be more pronounced for established
infections, as the thermal field is expected to penetrate the biofilm
more easily than diffusion of antibiotics, consistent with our findings
that bacterial cell death occurs throughout the biofilm (Figure S11) and that phanorod-Zn is still highly
effective when treatment is delayed, leading to a 50% reduction in
wound size 2–3 days after treatment, in contrast to systemic
fluoroquinolones, which showed relatively poor efficacy in the same
situation (a 50% reduction in wound size was achieved in 5–6
days with ciprofloxacin, which was only a ∼1 day improvement
compared to no treatment) (Figure ). Another advantage of phanorod-Zn is that the high
specificity and localized treatment may be advantageous for avoiding
undesirable effects on the microbiome.[110,111] Regardless,
the main benefit of an alternative antimicrobial strategy would be
as a last-line therapy for multidrug-resistant organisms.
Methods
Materials
Reagents were obtained
from the following
sources: gold(III) chloride trihydrate (HAuCl3, 99.9%,
Sigma), sodium borohydride (NaBH4, 98%, Fisher Scientific),
trisodium citrate dihydrate (99.9%; Sigma), P. aeruginosa (Schroeter) Migula (ATCC 25102; PAK strain), P. aeruginosa PAK-pmrB (gift of Prof. Jian Li, Monash University), V.
cholerae 0395 (gift of Prof. Michael J. Mahan, UCSB), M13KE
phage (New England Biolabs), M13-NotI-Kan construct,[45] sodium chloride (NaCl, 99%, Fisher BioReagents), tryptone
(99%, Fisher BioReagents), yeast extract (99%, Fisher BioReagents), E. coli ER2738 (New England Biolabs), N-(3-(dimethylamino)propyl)-N′-ethylcarbodiimide
hydrochloride (EDC, 99%, Sigma), N-hydroxysuccinimide
(NHS, 98%, Sigma), N-succinimidyl-S-acetylthiopropionate (SATP) (Thermo Fisher Scientific), 5-bromosalicylic
acid (5-BAA) (>98.0%; TCI), isopropyl β-d-1-thiogalactopyranoside
(IPTG) (99%; Fisher Scientific), thiol-PEG-acid (HOOC-PEG-SH; PEG
average Mn 5000; Sigma), poly(ethylene
glycol) (PEG-8000, Sigma), dialysis kit (MWCO 3500 Da, Spectrum Laboratories),
tetracycline (Sigma), kanamycin sulfate (Sigma), Top 10F′ cyan
cells (Thermo Fisher), Mix and Go competent cells (Zymo Research),
QIAprep Spin Miniprep Kit (Qiagen), QIAquick Gel Extraction Kit (Qiagen),
and KpnI-HF/NotI-HF restriction enzyme and T4 DNA
ligase (New England Biolabs), and Pseudomonas aeruginosa antibody (1010/287) (Novus Biologicals, LLC).
Pol-K Peptide
Design and Synthesis
The CXCX3CX2C
motif was previously identified in ca. 6% of the
Zn2+-binding sequences of the protein data bank (PDB).[112] Unlike other Zn2+-binding motifs
that can possess ligands to the metal center hundreds of amino acids
apart, this specific motif is only 10 amino acids long and is among
the shortest known binding sites that completely coordinate a metal
ion. The Pol-K peptide GCFCEDACDKCG was based on the Zn2+-binding sequence CFCEDHCDKC from RNA Polymerase II (PDB ID: 1i3q, chain C).[113] Glycines were added to the extremities of the
peptide to decrease the likelihood of interference from N- and C-termini
on coordination, while also facilitating functionalization by providing
spacing to the cysteine ligands. The histidine residue was substituted
with an alanine to remove competition with another potential ligand.Reagents for peptide synthesis were obtained from Sigma-Aldrich
and used without further purification. The synthesis of the Pol-K
peptide was performed according to standard Fmoc-based solid-phase
peptide synthesis procedures.[114]N,N-dimethyl formamide (DMF) was used as
the solvent, and Wang resin was used as the starting polymeric support.
Fmoc-protected amino acids (AA) were used. Peptide elongation was
by Fmoc-deprotection of the residue anchored to the resin and Fmoc-AA-OH
coupling. Fmoc-deprotection was by washing with 20% (v/v) piperidine
in DMF. For each coupling, an excess (Fmoc-AA-OH: anchored AA, 3:1)
of the Fmoc-α-amino acid derivative was added to the resin.
Apart from Fmoc-Cys(Trt)-OH, Fmoc-α-AA derivatives were activated
with a mixture of hydroxyl-benzotriazole (HOBt), N,N,N′,N′-tetramethyl-O-(benzotriazol-1-yl)uronium
tetrafluoborate, and N,N-diisopropylethyl
amine. Fmoc-Cys(Trt)OH was activated with a N,N′- diisopropylcarbodiimide (DIC)/HOBt mixture. The
peptide was cleaved from the resin and deprotected by treatment with
a solution of trifluoroacetic acid (TFA):H2O:triisopropyl
silane:1,2-ethanedithiol (volume ratio 37:1:1:1) for 2 h, and the
product was precipitated with a cold solution of diethyl ether followed
by washing cycles with diethyl ether. Finally, the peptide was dried
under vacuum. The successful synthesis was confirmed by mass spectrometry
using an Agilent 6530 LC-QTOF instrument (Agilent Technologies, Inc.)
with electrospray ionization (Figure S1e).Deionized (Milli-Q, Millipore) purified water was deoxygenated
by distillation under nitrogen. Solutions of Pol-K peptide were handled
under controlled nitrogen atmosphere with a Schlenk line and Schlenk
glassware and transferred to an anaerobic glovebox (Iteco Engineering)
for metalation and spectral acquisition. UV–vis absorption
spectra of freshly prepared solutions of peptido-metal complexes were
recorded with a Thermo Scientific Evolution 60S UV–visible
spectrophotometer inside of an anaerobic glovebox (Iteco Engineering).
Hellma high-performance quartz glass (QS) cuvettes were used for the
acquisition.
Peptide Zn2+-Binding Assay
To overcome the
spectroscopic silence of Zn2+, competitive binding experiments
were performed using a preformed peptido-Co2+ complex.
To form the saturated peptido-Co2+ complex, aliquots from
stocks of 333 mM and 33 mM metal salt solution (CoCl2·6H2O) were added into a cuvette containing 1 mL of 1 mM Pol-K
peptide and 20 mM glycylglycine at pH 8.7. UV–vis spectra were
collected upon each addition. Absorbance values at 750 nm, diagnostic
for tetrahedral 4S → Co2+ complexes,[48] were monitored until no further changes were
observed. The Kd of the peptido-Co2+ complex was calculated by fitting the absorbance data to
the equation:where Y is the absorbance, Bmax is the absorbance
at saturation, X is the concentration of Co2+, and h is the Hill coefficient. GraphPad Prism
v. 6.00 (GraphPad Software,
La Jolla California USA) for Windows was used to calculate the Kd values.To assay the competitive binding
of Zn2+, a decrease in the absorbance at 750 nm indicative
of the peptido-Co2+ complex was monitored after additions
of ZnSO4. The concentration of Co2+ added to
the peptide before the competition assay was equal to the Kd of the Pol-K-Co2+ complex, as determined
in saturation binding experiments. UV–vis spectra were collected
upon each addition. Titration continued until no change in absorbance
at 750 nm was observed. The Kd value of
the peptide-Zn2+ complex was calculated by fitting to a
revised Cheng–Prusoff equation for competitive inhibition,
as previously described[115] (Figure S1a–c).
Phage, Bacteria, and Gold
Nanorods
See Supporting Methods.
Synthesis of Phanorods and Phanorod-Zn
To prepare phanorods,
phages were chemically thiolated using SATP and conjugated to the
AuNRs, and trace CTAB was exchanged for HS-PEG-COOH.[24] Phanorod-Zn was prepared by coupling the −COOH groups
of phanorods with the amino groups of Pol-K through EDC chemistry.[22] A total of 1014 phanorods were reacted
with 1 mM EDC, 1 mM NHS, and 1 mM Pol-K (Zn2+ binding peptide)
in a volume of 2 mL of PBS buffer (pH 7.9) with gentle stirring at
room temperature. The same amount of EDC was added three more times
at time intervals of 30 min. The reaction was run overnight, and the
phanorod-Zn product purified by dialysis through regenerated cellulose
dialysis tubing (molecular weight cutoff of 3500 Da) in PBS buffer.
The concentration of the thiol groups from chemically conjugated Pol-K
was quantified with Ellman’s assay using a cysteine as a standard
(Figure S27a) and phanorods as control.[22,116] The number of Pol-K per phage was estimated by dividing the amount
of Pol-K (concentration of thiol groups divided by 4 cysteines per
Pol-K) by the number of phage particles, as quantified by real-time
PCR (Figure S4c).[22] The Zn2+ ions were loaded by incubating the phanorod-Zn
(1 mL of 1014/mL) with 1 mM ZnCl2 solution overnight
by gentle rotating. The product was collected after centrifugation
(12,000 rpm × 30 min) and washing 3× with water.
Zn2+ Release Experiments
The release behavior
of Zn2+ from phanorod-Zn (1014/mL) was investigated
in PBS buffer (pH 7.2) with or without laser irradiation for 15 min.
The samples were incubated at 37 °C after laser treatment, and
the released Zn2+ ions at different time points were collected
by high-speed centrifugation (12,000g for 30 min)
for ICP-MS analysis.
Inductively Coupled Plasma Mass Spectrometry
Measurement
ICP- MS analysis was performed with the NexION
2000 (PerkinElmer,
Inc.). Each sample was transferred to a clean Teflon vessel for acid
digestion. Digestion was carried out with a mixture of concentrated
HNO3 (65–70%, trace metal grade, Fisher Scientific)
and HCl (35–38%, trace metal grade, Fisher Scientific) in a
ratio of 1:3 with a supplement of H2O2 (30%,
certified ACS, Fisher Scientific) at 200 °C for 50 min in a microwave
digestion system (Titan MPS, PerkinElmer). The sample was cooled to
room temperature and subsequently diluted to a final volume of 50
mL by adding filtered DI water before analysis. The calibration curve
was established using a standard solution, using a dwell time of 50
ms with 30 sweeps and three replicates with background correction.
Transmission Electron Microscopy
TEM was performed
on a Tecnai FEI T12 electron microscope (CNSI, UCLA). The samples
were prepared by applying a few drops of solution onto TEM grids coated
with a 20 nm-thick carbon film.
Confocal Microscopy
Fluorescence images were obtained
on a Leica SP8 confocal microscope (Leica, Germany) with excitation
at 480 nm (CNSI, UCLA). The object-based colocalization was analyzed
by JACoP v2.0 (ImageJ), and the number of green objects was counted
(Ngreen) and their centers identified.
The number of these centers that colocalize with the center of a red
object (dead cells) was counted (Ncol).
The images were taken and analyzed by LAS X software.
Ultraviolet–vis
Spectra Measurement
UV–vis
absorbance spectra were collected on an HP 8453 UV–visible
spectrophotometer with a quartz spectrasil UV–vis cuvette using
direct detection at a slit width of 2 nm.
Attenuated Total Reflection
Infrared Spectra Measurement
The samples were completely
dried with lyophilization before the
measurement. ATR-FTIR spectra were measured with a Nicolet iS10 FTIR
using a MCT detector and a Harrick Scientific Corporation GATR accessory.
Photothermal Performance Measurements
The photothermal
stabilities of AuNRs, phanorods, and phanorod-Zn were analyzed by
irradiating the samples with NIR laser (1.2 W cm–2) for 6 min, and the samples were allowed to cool. This cycle was
repeated for another four times. The photothermal conversion efficiency
(η) of AuNR, phanorods, and phanorod-Zn was calculated by the
following equation (more details in Supporting Information):[117,118]where h is the heat transfer
coefficient, A is the surface area of the container, Tmax is the maximum temperature reached, Ts is the surrounding temperature, Q0 is the heat input due to light absorption by the solvent
(measured as 12.9 mW independently, using a quartz cuvette cell containing
pure water), I is the power density of the laser
applied (1.2 W cm–2), and A808 is the absorbance of the sample at 808 nm.Here, hA can be calculated by the following equation:where τS is the
system time
constant, and mH and CH are the mass of the water used
as solvent (1.0 g) and specific heat capacity of water (4.2 J/g),
respectively. In the natural cooling period, τS can
be calculated using the linear regression curve of the equation below:
Evaluation of Antibacterial
Effect In Vitro
The in
vitro antibacterial activity of phanorods and phanorod-Zn against P. aeruginosa, V. cholerae, and E. coli was quantitatively assessed by determination of
colony-forming units (cfu). 0.5 mL of bacterial suspension (1 ×
108 cfu/mL) was incubated with PBS (control), phanorod
(1014 phages/mL), or phanorod-Zn (1014 phages/mL)
in quartz cuvette cells with or without 808 nm laser irradiation (0.3
W cm–2) for 15 min. After the laser treatments,
the sample was diluted 1000-fold, and 10 μL was inoculated on
LB plates and incubated at 37 °C for 24 h. The cfu were counted,
and the survival rate of bacteria calculated.Additionally,
live/dead staining was performed to assay bacteriocidal activity,
according to the manufacturer’s protocol. The samples were
stained with a BacLight bacterial viability kit (Thermo Fisher Scientific)
and imaged on Leica SP8 confocal microscope. The antibody-AuNRs against P. aeruginosa were prepared according to previous report.[24] The in vitro antibacterial ability of antibody-AuNRs
was evaluated using the same method as described above for phanorods.
The concentration of the conjugated AuNRs was adjusted to be the same
as phanorod and phanorod-Zn ([Au] = 3.3 μM).
Evaluation
of In Vitro Ablation Effect of P. aeruginosa Biofilm
The P. aeruginosa biofilm was
prepared using a protocol modified from the literature.[119] A single colony of P. aeruginosa was used to inoculate LB and incubated in a shaker-incubator overnight
at 37 °C. The culture was diluted 100-fold into fresh medium,
and 150 μL of the dilution was added to Lab-Tek plates (culture
area, 0.7 cm2) for overnight incubation at 37 °C.
Then, the liquid was removed by turning the plate over and shaking.
The remaining biofilm was washed two times by submerging the plate
in a small tub of water and shaking out the water. 300 μL of
phanorod or phanorod-Zn (1014 phages per mL, 3.3 μM
Au) or antibody-AuNRs (3.3 μM Au, ∼2 × 1015 AuNRs) was added to the biofilm and incubated for 30 min. Unbound
bioconjugates in suspension were removed by pipetting. The biofilm
was irradiated with the NIR laser for 15 min as described above. Cell
viability was studied by resuspending the bacteria and growing aliquots
on LB plates (1 μL of cell suspension was diluted in 1 mL of
PBS buffer, and 5 μL of the dilution was plated) for colony
counting and by confocal microscopy with live/dead cell viability
staining with SYTO9 and PI (Filmtracer LIVE/DEAD biofilm viability
kit, Thermo Fisher Scientific).
Mouse Model of P. aeruginosa-Infected Wounds
All animal procedures
were conducted in accordance with institutional
guidelines and approved by the UCLA Institutional Animal Care and
Use Committee (Protocol ARC-2020-044). 12–15 weeks-old male
and female mice (22–25 g, strain 027-C57BL/6 from Charles River
Laboratories, MA, USA) were randomly assigned to different groups.
Wound exposure to PBS buffer was used as the negative control group.
Phanorod and phanorod-Zn treatments were used in the experimental
groups, and antibody-AuNRs were used as a comparison group. The following
standard clinical treatment methods were applied as positive control
groups: two systemic antibiotics (ciprofloxacin and levofloxacin,
orally fed), one topical antibiotic (polysporin), and two topical
antiseptics (acetic acid and chlorhexidine).On day 0, the mice
were anaesthetized by isoflurane vaporized in O2 (2.5%)
prior to surgery and placed upon a sterile towel on a warm pad with
circulating water. The dorsal side was shaved, depilated, and then
disinfected with ethanol pads and povidone iodine swabs. An artificial
wound ∼6 mm long (or ∼12 mm long for the large wound
group) was made on the dorsum of each mouse with a scissor, resulting
in an initial wound area of ∼8.5 mm2 (or ∼17.6
mm2 for the large wound group). Wounds were inoculated
with 20 or 100 μL of P. aeruginosa (5 ×
108 cfu/mL) and incubated for 1 h.For wound treatment
by PBS (control), phanorod (1014/mL in PBS), phanorod-Zn
(1014/mL in PBS), or antibody-AuNR
(3.3 uM in PBS), a particle suspension (∼50–100 μL)
was applied and incubated for 30 min, followed by 808 nm laser irradiation
(0.3 W cm–2, unless otherwise specified) for 15
min. Unless otherwise specified, phanorod and phanorod-Zn treatment
(reagent application followed by irradiation) was performed on day
0, with a second round of irradiation also applied on day 1. Alternative
treatment regimens included treatment on day 2 with a second round
of irradiation on day 3 or single treatment on day 0. For systemic
antibiotics, treatment was applied by feeding the antibiotics orally
(250 mg kg–1 day–1). The topical
antibiotic and antiseptic treatments were applied by covering the
wound area with polysporin ointment (Johnson & Johnson Consumer
Inc.), 4% chlorhexidine (McKesson Corporation), or 2% acetic acid
(Akorn Pharmaceuticals). The antibiotics and antiseptics were applied
every 24 h unless stated otherwise.To evaluate the therapeutic
effect, wounds were photographed (by
iPhone 8) at regular time intervals, and wound size was measured by
a ruler. For analysis of cfu, mice were sacrificed, and the wound
tissue harvested, weighed, chopped, and homogenized in PBS buffer.
The homogenized samples were centrifuged at 3000g for 6 min to pellet debris, and 100 μL of supernatant was
plated onto LB agar for CFU counting. For histomorphological analysis,
wound tissue was fixed with 4% paraformaldehyde solution and washed
with 75% ethanol. The tissue samples were analyzed by H&E staining[120] or Masson’s trichrome staining[121] (performed by the Translational Pathology Core
Laboratory (TPCL) at UCLA). The relative collagen area was determined
using ImageJ. The area of collagen was measured by manual adjustment
of a threshold value in the blue channel to match visual inspection.
Similarly, the area of the tissue was measured by manual adjustment
of the threshold in all color channels to match visual inspection.
To assess toxicity, the major organs (heart, liver, spleen, lungs,
and kidneys) of the mice were stained by H&E on day 10, and blood
and serum were collected for biochemical analysis (performed by IDEXX
Laboratories) on day 10. The concentrations of Zn2+ and
Au3+ ions were measured by ICP-MS as described above.To evaluate delayed treatment by phanorod-Zn, an experimental group
was treated with phanorod-Zn on days 2 and 3 (phanorod-Zn was applied
only on day 2 and irradiated with laser on days 2 and 3) and compared
to a control group with ciprofloxacin treatment starting from day
2.No unexpected or unusually high safety hazards were encountered.
Statistical Analysis
All the quantitative data in each
experiment are presented as mean ± standard deviation of at least
three independent experiments. Student’s t test (two-sided) was utilized to evaluate the statistical significance.
Values of p < 0.05 (*), p <
0.01 (**) and p < 0.001 (***) were considered
statistically significant.
Authors: C Vairo; M Collantes; G Quincoces; S Villullas; I Peñuelas; M Pastor; A G Gil; E Gainza; R M Hernandez; M Igartua; G Gainza Journal: Int J Pharm Date: 2019-06-28 Impact factor: 5.875
Authors: Katherine L Petrie; Nathan D Palmer; Daniel T Johnson; Sarah J Medina; Stephanie J Yan; Victor Li; Alita R Burmeister; Justin R Meyer Journal: Science Date: 2018-03-30 Impact factor: 47.728
Authors: Christopher A McDevitt; Abiodun D Ogunniyi; Eugene Valkov; Michael C Lawrence; Bostjan Kobe; Alastair G McEwan; James C Paton Journal: PLoS Pathog Date: 2011-11-03 Impact factor: 6.823